Mackiewicz, Jacek http://orcid.org/0000-0002-0177-2972
Burzykowski, Tomasz
Iżycki, Dariusz
Mackiewicz, Andrzej
Funding for this research was provided by:
INNOMED/6/I/NCBR/2014 (INNOMED/6/I/NCBR/2014)
Article History
Received: 10 September 2018
Accepted: 16 November 2018
First Online: 29 November 2018
Ethics approval and consent to participate
: Human investigations were performed after approval by an institutional review board or ethics committee in accordance with an assurance filed with and approved by the Polish Ministry of Health. Written informed consent was obtained from all patients.
: Not applicable.
: J. Mackiewicz – advisory board Bristol-Myers Squibb; speakers’ bureau – Bristol-Myers Squibb; GlaxoSmithKline, Roche, MSD, Novartis; travel reimbursement: Bristol-Myers Squibb, GlaxoSmithKline, Roche, MSD, Novartis.A. Mackiewicz – is a shareholder of BioContract Sp. z o.o. (contract vaccine manufacturing company); travel reimbursements: Roche, Bristol-Myers Squibb.T. Burzykowski - no competing interests reported.D. Iżycki - no competing interests reported.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.